SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Change in Account Payables of $685000.0 for Q1 2026, up 147.29% year-over-year from $277000.0 in Q1 2025, and up 3.79% quarter-over-quarter from $660000.0 in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Change in Account Payables for 17 consecutive years, with $685000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 147.29% year-over-year to $685000.0; the TTM figure through Mar 2026 stood at -$127000.0 (up 96.54% YoY), while the FY2025 annual figure was -$535000.0, up 74.99% from the prior year.
- Change in Account Payables rose to $685000.0 in Q1 2026 per SLS's latest filing, from $660000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.8 million in Q1 2024 and bottomed at -$1.8 million in Q3 2024.
- Historically, Change in Account Payables has averaged $89705.9 across 5 years, with a median of $528000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 550.56% — and 2024, when it jumped 735.92%.
- SELLAS Life Sciences' Change in Account Payables stood at $1.2 million in 2022, then increased by 7.15% to $1.3 million in 2023, then tumbled by 184.83% to -$1.1 million in 2024, then soared by 159.03% to $660000.0 in 2025, then climbed by 3.79% to $685000.0 in 2026.
- Business Quant data shows SLS's Change in Account Payables at $685000.0 in Q1 2026, $660000.0 in Q4 2025, and -$1.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | -547,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -547,000.00 |
| Mar 31, 2026 | 685,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | -1.77 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 606,000.00 |
| Jun 30, 2023 | 661,000.00 |
| Mar 31, 2023 | -284,000.00 |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | -1.21 Mn |
| Jun 30, 2022 | 528,000.00 |
| Mar 31, 2022 | 667,000.00 |
| Dec 31, 2021 | -401,000.00 |
| Sep 30, 2021 | 269,000.00 |